kiovig

Kiovig is a highly purified human normal immunoglobulin (IgG) preparation derived from pooled human plasma. It is used as an intravenous or subcutaneous immunoglobulin replacement therapy for patients with primary and certain secondary immunodeficiencies, as well as for various autoimmune and inflammatory conditions. The mechanism of action in replacement therapy is to restore abnormally low IgG levels to the normal range in the blood, thereby supporting the immune system’s ability to fight infections. At higher doses, Kiovig exerts immunomodulatory effects by modulating abnormal immune responses—though these mechanisms are not fully elucidated. Kiovig has been approved for use in multiple countries under different brand names (notably Gammagard Liquid in the US/Canada). It is indicated for primary immunodeficiency disorders (PID), symptomatic hypogammaglobulinaemia secondary to disease or treatment, idiopathic thrombocytopenic purpura (ITP), Guillain-Barré syndrome, Kawasaki disease, chronic inflammatory demyelinating polyradiculoneuropathy (CIDP), multifocal motor neuropathy (MMN), and other antibody deficiency states[1][3][4][5][6].

Brand names

kiovig

Other names

gammagard liquidhuman normal immunoglobulinimmune globulin intravenous (human) 10% solution